Home
  >  
Section 69
  >  
Chapter 68,906

Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers

Liu, Y.; Lu, C.; Chen, Q.; Wang, W.; Liu, G.-Y.; Lu, X.-P.; Zhang, M.-Q.; Yu, C.; Jia, J.-Y.

Drug Research 63(2): 74-78

2013

ISSN/ISBN: 2194-9379
PMID: 23447077
DOI: 10.1055/s-0032-1331768
Accession: 068905848
Download citation:  
Text
  |  
BibTeX
  |  
RIS
Carvedilol is a nonselective-blocking agent and is used in the treatment of hypertension and angina pectoris. The aim of this study was to evaluate bioequivalence of two 25-mg tablet formulations of carvedilol following single oral dose in adult male volunteers. This was a randomized, single-dose, open-label, crossover bioequivalence study. Plasma samples were collected before dosing and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 h after dosing. Plasma concentrations of Carvedilol were determined by using a validated LC-MS/MS method. Statistical analysis of the pharmacokinetic parameters Cmax, AUC0-24, and AUC0-∞ was conducted to determine bioequivalence. 23 healthy male Chinese volunteers were enrolled in the study. The mean (SD) Cmax, AUC0-24, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 73.71 (34.04) vs. 78.93 (43.64) ng/mL, 285.1 (147.0) vs. 296.9 (176.1) ng/mL · h, and 296.5 (161.4) vs. 303.4 (177.9) ng/mL · h. The 90% CIs of the ratios (test vs. reference) for the ln-transformed Cmax, AUC0-24, and AUC0 - ∞ were 85.3% to 114.3%, 90.4% to 107.6%, and 90.9% to 108.4%, respectively, meeting the criteria of SFDA, FDA and EMEA for bioequivalence. The relative bioavailability of the test formulation to reference formulation was 100.1%. Both formulations were generally well tolerated and no serious AEs were reported in the study. The 90% CIs for the ratios of mean Cmax, AUC0-24, and AUC0-∞ met the regulatory criteria for bioequivalence.

Full Text Article emailed within 0-6 h: $19.90




Related References

Liu, Y.; Lu, C.; Chen, Q.; Wang, W.; Liu, G.Y.; Lu, X.P.; Zhang, M.Q.; Yu, C.; Jia, J.Y. 2013: Bioequivalence and Pharmacokinetic Evaluation of Two Tablet Formulations of Carvedilol 25-mg: A Single-Dose, Randomized-Sequence, Open-Label, Two-Way Crossover Study in Healthy Chinese Male Volunteers Drug Research (Stuttgart 2013. Print) 63(2): 74-78
Liu, Y.; Zhang, M.-q.; Zhu, J.-m.; Jia, J.-y.; Liu, Y.-m.; Liu, G.-y.; Li, S.; Weng, L.-p.; Yu, C. 2010: Bioequivalence and pharmacokinetic evaluation of two formulations of glimepiride 2 mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers Clinical Therapeutics 32(5): 986-995
Liu, Y-Mei.; Liu, G-Yi.; Liu, Y.; Li, S-Jun.; Jia, J-Ying.; Zhang, M-Qi.; Lu, C.; Zhang, Y-Mei.; Li, X-Ning.; Yu, C. 2009: Pharmacokinetic and bioequivalence comparison between orally disintegrating and conventional tablet formulations of flurbiprofen: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male volunteers Clinical Therapeutics 31(8): 1787-1795
Zou, J.-J.; Ji, H.-J.; Wu, D.-W.; Yao, J.; Hu, Q.; Xiao, D.-W.; Wang, G.-J. 2008: Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study Clinical Therapeutics 30(9): 1651-1657
Liu, Y.; Zhang, M.-q.; Jia, J.-y.; Liu, Y.-m.; Liu, G.-y.; Li, S.-j.; Wang, W.; Weng, L.-p.; Yu, C. 2013: Bioequivalence and pharmacokinetic evaluation of two formulations of risperidone 2 mg : an open-label, single-dose, fasting, randomized-sequence, two-way crossover study in healthy male Chinese volunteers Drugs in R&d 13(1): 29-36
Zou, J.; Di, B.; Wu, C.Yong.; Hu, Q.; Li, J.Hua.; Zhu, Y.; Fan, H.; Xiao, D.; Wang, G.Ji. 2008: Pharmacokinetic and bioequivalence comparison of a single 100-mg dose of cefteram pivoxil powder suspension and tablet formulations: a randomized-sequence, open-label, two-period crossover study in healthy Chinese adult male volunteers Clinical Therapeutics 30(4): 654-660
Jin, J.; Liu, J.; Chen, J.; Zhao, L.; Ma, Z.; Chen, X.; Huang, M.; Zhong, G. 2012: Bioequivalence evaluation of 2 tablet formulations of entecavir in healthy chinese volunteers: a single-dose, randomized-sequence, open-label crossover study Arzneimittel-Forschung 62(3): 113-116
Liu, M.-Y.; Wang, S.; Yao, W.-F.; Wu, H.-z.; Meng, S.-N.; Wei, M.-J. 2009: Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers Clinical Therapeutics 31(4): 784-792
Zhang, Q.; Tao, Y.; Zhu, Y.; Zhu, D. 2010: Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study Clinical Therapeutics 32(1): 171-178
Wu, H.; Liu, M.; Wang, S.; Feng, W.; Yao, W.; Zhao, H.; Wei, M. 2010: Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers Clinical Therapeutics 32(3): 597-606
Yu, J.; Ma, K.; Qi, J.; Jin, G.; Wang, Y.; Fang, S.; Li, G. 2008: Bioequivalence and comparison of pharmacokinetic properties of 4-mg tablet formulations of rosiglitazone hydrochloride and rosiglitazone maleate: a single-dose, randomized, open-label, two-period crossover study in healthy adult male Chinese volunteers Clinical Therapeutics 30(12): 2272-2279
Choi, H.-G.; Jeon, J.-Y.; Im, Y.-J.; Kim, Y.; Jang, H.; Kang, S.; Kim, K.H.; Chae, S.-W.; Lee, S.Y.; Kim, M.-G. 2014: Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study International Journal of Clinical Pharmacology and Therapeutics 52(1): 55-63
Zhu, Y.; Zou, J.; Xiao, D.; Fan, H.; Yu, C.; Zhang, J.; Yang, J.; Guo, D. 2009: Bioequivalence of two formulations of glucosamine sulfate 500-mg capsules in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, fasting, two-way crossover study Clinical Therapeutics 31(7): 1551-1558
Wang, S.; Ren, J.; Wang, H.; Zhi, T.; Zhu, Y.; Feng, J.; Li, Z.; Zhang, R. 2022: Bioequivalence and Pharmacokinetic Evaluation of 2 Pyrazinamide Formulations in Healthy Chinese Adults: a Single-Dose, Open-Label, Randomized-Sequence, 2×2 Crossover Study Clinical Pharmacology in Drug Development 11(4): 551-556
Maanen, R.v.; Bentley, D. 2009: Bioequivalence of zonisamide orally dispersible tablet and immediate-release capsule formulations: results from two open-label, randomized-sequence, single-dose, two-period, two-treatment crossover studies in healthy male volunteers Clinical Therapeutics 31(6): 1244-1255
Di Girolamo, G.; Czerniuk, P.; Bertuola, R.; Keller, G.A. 2010: Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study Clinical Therapeutics 32(1): 161-170
Liu, Y.; Jia, J.; Liu, G.; Li, S.; Lu, C.; Liu, Y.; Yu, C. 2009: Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers Clinical Therapeutics 31(4): 777-783
Zhai, X.-J.; Hu, K.; Chen, F.; Lu, Y.-N. 2013: Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study Current Therapeutic Research 75: 48-52
Jia, J.-Y.; Zhang, M.-Q.; Liu, Y.-M.; Liu, Y.; Liu, G.-Y.; Li, S.-J.; Lu, C.; Weng, L.-p.; Qi, Y.-L.; Yu, C. 2010: Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers Clinical Therapeutics 32(7): 1387-1395
Shi, S.; Liu, Y.; Wu, J.; Li, Z.; Zhao, Y.; Zhong, D.; Zeng, F. 2010: Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study Clinical Therapeutics 32(11): 1977-1986